1 Year into the NICE TA- your achievements and challenges

National Institute for Health & Care Excellence (NICE) Technology Appraisal Guidance on HCL technology - 2023

Hybrid closed loop (HCL) systems are recommended as an option for managing blood glucose levels in type 1 diabetes for:

- -children & young people,
- -people who are pregnant or planning a pregnancy, and
- —adults who have an HbA1c of ≥ 58 mmol/ mol (≥ 7.5%), or have disabling hypoglycaemia, despite best possible management with at least 1 of the following:
 - continuous subcutaneous insulin infusion (CSII)
 - -real-time continuous glucose monitoring
 - -intermittently scanned continuous glucose monitoring

What is the challenge?

- Based on NDA report 2021 there are **236,000 people** aged 19 and over living with T1D
 - 85,840 are seen in specialist care
 - 137,765 are in primary care only
- Data from the NDA suggests that approximately 140 000 adults across England and Wales may be eligible for HCL treatment based on the HbA1c criteria alone.
- NICE TA151 for insulin pump therapy in people with type 1 diabetes was published in July 2008.
 - Only 11.5% of people with type 1 diabetes in England are using CSII and 16.7% of those in Wales.
 - That corresponds to just over **26 000** people from a total population of 227 435 who have accessed insulin pump therapy over a 15-year period.
 - Estimated that just under 60 000 people met HbA1c criteria for insulin pump therapy
- To roll out HCL to the eligible population who would like to access it, the pace of offering access to technology will
 need to increase rapidly.
- This represents a significant challenge to services keen to offer access to this life-changing technology.
- We have 5 years to do this......
- We must do something different

HCL implementation- Key considerations....

Service capacity

Administration

HCP education

Education and Sharing

Best Practice

Funding

PWD awareness and education

1 Year On...Let's celebrate achievements so

• HCL is happening across the country, its hard but lets not forget the bigger picture.

far

- Priority areas:
 - Pregnancy
 - Children and Young adults (nearly 70%)
- Allocation of local funding
 - Signed up to NHS Framework
 - Data collection
 - 60 million for year 2
 - 1 million pregnancy swap fund
- Education and confidence around HCL increasing
 - Conferences
 - Study days
 - Insulin safety week.
 - Team education

THE STORY OF 2024


97% of T1Diabetes have CGM

98% of T1Diabetes pregnancy have CGM

Pediatric HbA1c attainments best since records began


Adults HbA1c attainments best since records began


T1Diabetes pregnancy outcomes - improvement on all markers







HbA1c < 7.5%....Moments in Time







Tackling deprivation (Paediatric)





Tackling Ethnicity gaps (Paediatric)





Slido

• What successes are you proud of in the last year with the Implementation of HCL?

Slido

What blocks/challenges are you facing in your area with the implementation of HCL?

Hybrid Closed Loop Workforce Capacity Modelling Tool.





The HCL Workforce Capacity Modelling Tool is designed to assist with:

a) Forecasting:

- Type 1 diabetes caseloads
- HCL uptake rates
- Outpatient clinic requirements
- Education class needs

b) Capacity Planning:

• Estimating educator and administrative workforce requirements across the HCL pathway, including structured education sessions.

Explore the tool here:

• https://healthinnovationnetwork.com/resources/hybrid-closed-loop-workforce-capacity-modelling-tool/

- This tool is a free resource, and we encourage you to download and share it with Type 1 Diabetes services and commissioners across the country.
- To access the tool, you'll be asked to provide some brief information about yourself and grant consent to receive updates. This will ensure you are notified of future versions of the tool, which we plan to update as guidance evolves or new devices are added to the framework.

Hybrid Closed Loop Demand & Capacity Model - Outputs Dashboard

Return to Navigatio

1.5


25/26


26/27

27/28

Health Innovation Network

This page shows the impact on caseload, mix of therapy types and activity, and the capacity, workforce and devices needed to support the HCL starts & upgrades profile configured by the user.





Activity				
24/25	25/26	26/27	27/28	28/29
1,329	1,473	1,513	1,543	1,570
199	928	927	925	779
2,720	2,818	2,902	2,976	3,037
22	95	94	94	78
: 19	50	50	50	33
20	20	20	20	0
81	143	143	143	81
	24/25 1,329 199 2,720 22 19 20	24/25 25/26 1,329 1,473 199 928 2,720 2,818 22 95 19 50 20 20	24/25 25/26 26/27 1,329 1,473 1,513 199 928 927 2,720 2,818 2,902 22 95 94 19 50 50 20 20 20	24/25 25/26 26/27 27/28 1,329 1,473 1,513 1,543 199 928 927 925 2,720 2,818 2,902 2,976 22 95 94 94 19 50 50 50 20 20 20 20

Devices							
Activity type	24/25	25/26	26/27	27/28	28/29		
Dexcom G6 transmitter PLUS sensor	144	214	216	218	228		
Abbott Freestyle Libre 3	30	45	45	46	48		
Medtronic G4	23	34	34	34	36		
Simplera Sync	8	11	11	11	12		
ALL OTHER CGM SENSORS	11	17	17	17	18		
TOTAL CGM SENSORS	216	320	323	326	341		
Insulet Omnipod 5	129	190	192	194	203		

F2F outpatient

clinic

28/29

24/25

25/26


26/27


27/28

Educator

Risk Stratification

 The model predicts that, without risk stratification, demand for diabetes educators will grow by 24% from 2024/25 to 2025/26.
 Successful risk stratification approaches might reduce this by more than half.





Comprehensive resources to support healthcare teams, including:

